Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DSTP3086S · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Dose escalation cohorts |
| B | EXPERIMENTAL | Dose expansion cohorts |
| Name | Type | Description |
|---|---|---|
| DSTP3086S | DRUG | DSTP3086S administered intravenously |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Life expectancy of at least 12 weeks * Histologic documentation of adenocarcinoma of the prostate * Surgical castration or ongoing use of gonadotropin-releasing hormone agonists with confirmed castrat...
Top 20 of 53 competitors
DSTP3086S is an investigational small molecule being studied for the treatment of metastatic castration-resistant prostate cancer. It is in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated for its safety and pharmacokinetics in patients with this condition.
DSTP3086S is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational oncology drug for prostate cancer. Roche is responsible for the development and clinical testing of DSTP3086S.
DSTP3086S is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial is complete, and the drug remains under investigation for metastatic castration-resistant prostate cancer.
DSTP3086S has one completed clinical trial, NCT01283373, which was a Phase 1 study of the safety and pharmacokinetics of escalating doses in patients with metastatic castration-resistant prostate cancer. The trial enrolled 84 participants in the United States and was a controlled, non-randomized study.
DSTP3086S is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for metastatic castration-resistant prostate cancer. The completed Phase 1 trial assessed safety and pharmacokinetics, but the drug has not received marketing approval.